hVIVO PLC - >£5 million CRS contracts signed

hVIVO plc
("hVIVO", the "Company" or the "Group")
>
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over
The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS' strong reputation and long-standing relationships in
The trials will take place at the Mannheim and Kiel sites studying drug candidates targeting multiple therapeutic areas including cardiometabolic, dermatology, infectious disease, renal impairment, and cancer. CRS has strong expertise across this range of therapeutic areas, expanding the Group's addressable market. Venn Life Sciences will be supporting these contracts with its Biometry service, demonstrating the cross-selling benefits being realised from the integration of CRS into the Group.
CRS have conducted over 1,800 clinical trials and provides advice to its clients across every aspect of their study, from feasibility and study design to trial management, recruitment, execution, and close-out. These studies span Phase I and Phase II in healthy volunteers and patients, supported by CRS' participant recruitment platform, recently enhanced by hVIVO's Volunteer Management System improving efficiency in recruitment for CRS trials.
Professor
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin 'Mo' Khan, Chief Executive Officer |
|
|||
|
|
|
|||
|
Cavendish Capital Markets Limited (Nominated Adviser |
+44 (0)20 7220 0500 |
|||
|
|
|
|||
|
|
|
|||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr |
|
|||
|
|
|
|||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
|
|
|||
|
|
|
|||
|
Walbrook PR (Financial PR & IR) |
+44 (0)20 7933 8780 or hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654/ |
|||

Notes to Editors
hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.
hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in
Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.
The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE